ZDF
Sign inSign up

Vulnerabilities

Vulnerability · CVE-2025-3823

A vulnerability classified as problematic has been found in SourceCodester Web-based Pharmacy Product Management System 1.0.

Published Apr 20, 2025 · catalog updated Apr 21, 2025 · SourceCodester Web-based Pharmacy Product Management System

Check if you run it

No confirmed exploitation is on record for CVE-2025-3823. EPSS is 0.41%. Act only if a listed version of SourceCodester Web-based Pharmacy Product Management System is installed.

Gaps on this record

  • No vendor fix or required action is stored. Compare the linked advisory before you change production.
Severity
Medium4.8
Known exploitation
Not in CISA/VulnCheck KEV
EPSS
0.41%
Remediation
Vendor / distro source
Affected products
vendor SourceCodester Web-based Pharmacy Product Management System 1.0

A vulnerability classified as problematic has been found in SourceCodester Web-based Pharmacy Product Management System 1.0. Affected is an unknown function of the file add-stock.php. The manipulation of the argument txttotalcost/txtproductID/txtprice/txtexpirydate leads to cross site scripting. It is possible to launch the attack remotely. The exploit has been disclosed to the public and may be used.

Are you affected?

Enter the version you run. The result uses only the ranges stored on this record.

The check returns affected, not affected, or incomplete. It does not guess a version that is missing from the record.

  • vendor SourceCodester Web-based Pharmacy Product Management System 1.01.0

How to fix CVE-2025-3823

What to do

Three questions, each answered from this record only. Confirm the vendor advisory before you patch.

Should you patch?

No confirmed exploitation is on record for CVE-2025-3823. EPSS is 0.41%. Act only if a listed version of SourceCodester Web-based Pharmacy Product Management System is installed.

Which versions are affected?

Compare what you have installed with SourceCodester Web-based Pharmacy Product Management System 1.0 1.0. Compare the installed version with the linked vendor advisory before you change production.

What should an analyst verify?

No weakness class is stored. EPSS 0.41%. There is no CISA KEV listing. No Exploit-DB or Metasploit reference is linked. Use the source links for the original advisory.

Code

The project this record applies to. Exploit listings stay in References.

Timeline

Detection, updates, and resolution for this record.

  1. Apr 20, 2025 · EUVD

    Detected

    A vulnerability classified as problematic has been found in SourceCodester Web-based Pharmacy Product Management System 1.0. Affected is an unknown function of the file add-stock.php. The manipulation of the argument txttotalcost/txtproductID/txtprice/txtexpirydate leads to cross site scripting. It is possible to launch the attack remotely. The exploit has been disclosed to the public and may be u

  2. Apr 21, 2025 · EUVD

    Updated

    A vulnerability classified as problematic has been found in SourceCodester Web-based Pharmacy Product Management System 1.0. Affected is an unknown function of the file add-stock.php. The manipulation of the argument txttotalcost/txtproductID/txtprice/txtexpirydate leads to cross site scripting. It is possible to launch the attack remotely. The exploit has been disclosed to the public and may be u

Sources

  • CVE.orgVulnerability recordCVE-2025-3823

    Official CVE identifier

    cve.org
  • FIRST EPSSExploitation probabilityCVE-2025-3823

    30-day exploitation probability 0.4%

    first.org
  • EUVDVulnerability recordEUVD-2025-11950

    A vulnerability classified as problematic has been found in SourceCodester Web-based Pharmacy Product Management System 1.0. Affected is an unknown function of the file add-stock.php. The manipulation of the argument txttotalcost/txtproductID/txtprice/txtexpirydate leads to cross

    euvd.enisa.europa.eu

References

Freshness

Last verified in this catalog Oct 18, 2026. Significant claims (KEV, EPSS, CVSS, affected ranges) come from the source rows above — open the original publisher for the authoritative advisory.